ESTTA Tracking number:

ESTTA568094 10/30/2013

Filing date:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

### **Notice of Opposition**

Notice is hereby given that the following party opposes registration of the indicated application.

### **Opposer Information**

Name	Novartis AG
Granted to Date of previous extension	10/30/2013
Address	CH-4002 Basel, SWITZERLAND

Attorney	Maury M. Tepper, III
information	Tepper & Eyster, PLLC
	3724 Benson Drive
	Raleigh, NC 27609
	UNITED STATES
	mtepper@teiplaw.com Phone:919-861-8903

### **Applicant Information**

Application No	79121577	Publication date	07/02/2013
Opposition Filing Date	10/30/2013	Opposition Period Ends	10/30/2013
International Registration No.	1138830	International Registration Date	09/04/2012
Applicant	UCB PHARMA, S.A. Allée de la Recherche 60 B-1070 BRUXELLES, BEX BEX		

## Goods/Services Affected by Opposition

Class 005. First Use: 0 First Use In Commerce: 0

All goods and services in the class are opposed, namely: Pharmaceutical preparations and substances for the treatment of immunology disorders, pharmaceutical preparations and substances for the treatment of central nervous system diseases

### **Grounds for Opposition**

l	Priority and likelihood of confusion	Trademark Act section 2(d)	
		•	

### Mark Cited by Opposer as Basis for Opposition

U.S. Application No.	85501826	Application Date	12/22/2011
Registration Date	NONE	Foreign Priority Date	NONE



Word Mark	SEEBARI
Design Mark	SEEBARI
Description of Mark	NONE
Goods/Services	Class 005. First use: First Use: 0 First Use In Commerce: 0 Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparationsfor the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for use in dermatology; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceuticals, namely, anti-infectives

Attachments	85501826#TMSN.jpeg( bytes ) SENBARI Notice of Opposition.pdf(1603462 bytes )
-------------	--

### **Certificate of Service**

The undersigned hereby certifies that a copy of this paper has been served upon all parties, at their address record by First Class Mail on this date.

Signature	/Maury M. Tepper, III/
Name	Maury M. Tepper, III
Date	10/30/2013



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

In the matter of Trademark Application Serial No. 79/121,577

Filed September 4, 2012 For the Mark SENBARI		
Novartis AG,	)	
	)	
Opposer,	)	
	)	
v.	) Opposition No.	
	)	
	)	
UCB PHARMA, S.A,	)	
	)	

### NOTICE OF OPPOSITION

)

Opposer Novartis AG, CH-4002, Basil, Switzerland, believes that it will be damaged by registration of the mark shown in Application Serial No. 79/121,577, and hereby opposes the same.

The grounds for opposition are as follows:

Applicant.

- 1. Applicant filed Application Serial No. 79/121,577 on or about September 4, 2012, to register the mark SENBARI in connection with "Pharmaceutical preparations and substances for the treatment of immunology disorders, pharmaceutical preparations and substances for the treatment of central nervous system diseases" in Class 5 ("Applicant's Mark").
- 2. Opposer will be damaged by the registration of Applicant's Mark.



- 3. Opposer is the owner of United States Trademark Application No. 85/501,826 for the mark SEEBARI, filed on December 22, 2011, for "Anti-inflammatories: Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Pharmaceutical preparations acting on the central nervous system: Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases: Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders: Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in dermatology: Pharmaceutical products for ophthalmological use: Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceuticals, namely, antiinfectives" ("Opposer's Mark").
- 4. The filing date for Opposer's Mark (December 22, 2011) is prior to any priority date that Applicant can claim relating to Applicant's Mark.
- Applicant's Mark so resembles Opposer's Mark as to be likely to cause confusion,
   or to cause mistake or to deceive.



WHEREFORE, Opposer prays that said application Serial No. 79/121,577, be rejected, that no registration be issued, and that this Opposition be sustained in favor of Opposer.

This the 30th day of October, 2013.

Respectfully submitted.

Maury M. Tepper, III Kathryn M. Eyster Tepper & Eyster, PLLC (919) 861-8901 telephone (919) 861-8913 telefax mtepper@teiplaw.com

Attorneys for Opposer



# DOCKET

## Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

